|Pirinixil (BR-931) Catalog No.GC31488|
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
Male Sprague-Dawley rats, weighing 220 to 230 g at the start of each experiment, are used in all studies. They are kept in an air-conditioned environment, with controlled lighting and free access to water. Dietary treatments are (A) standard diet for rats and (B) 2% cholesterol+2% cholic acid regimen. Both diets are administered ad libitum, respectively for 1 and 2 weeks (standard diet) and for 2 weeks (cholesterolcholic acid diet). Groups of 5 rats in each of the 3 experiments (1 and 2 weeks with the standard diet, 2 weeks with the cholesterol-cholic acid diet) are administered Pirinixil daily in carboxymethylcellulose vehicle by gastric intubation, at the doses of 20 mg/kg. Controls are given a similar volume of vehicle daily by intubation.
. D'Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83.
|Cas No.||65089-17-0||SDF||Download SDF|
|Solubility||Soluble in DMSO||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
Pirinixil is a hypolipidemic agent of low toxicity.
Pirinixil is a hypolipidemic agent of low toxicity. Total cholesterol is reduced by Pirinixi in the spleen, kidney and heart of rats. Pirinixil decreases the estimated total body cholesterol approximately 40%. Pirinixil increases plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides are markedly reduced by Pirinixil, while combined plasma and liver lipid levels decrease approximately 20%. Liver HMG-CoA reductase activity is not affected, but cholesterol 7α-hydroxylase is significantly reduced by Pirinixil.
. D'Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83. . Kritchevsky D, et al. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil(BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82.